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Abstract
Dystroglycan (DG) is a membrane receptor, belonging to the dystrophin-glycoprotein com-
plex (DGC) and formed by two subunits, α-dystroglycan (α-DG) and β-dystroglycan (β -DG).
The C-terminal domain of α-DG and the N-terminal extracellular domain of β -DG are con-
nected, providing a link between the extracellular matrix and the cytosol. Under pathological
conditions, such as cancer and muscular dystrophies, DG may be the target of metallopro-
teinases MMP-2 and MMP-9, contributing to disease progression. Previously, we reported
that the C-terminal domain α-DG (483–628) domain is particularly susceptible to the cata-
lytic activity of MMP-2; here we show that the α-DG 621–628 region is required to carry out
its complete digestion, suggesting that this portion may represent a MMP-2 anchoring site.
Following this observation, we synthesized an α-DG based-peptide, spanning the (613–
651) C-terminal region. The analysis of the kinetic and thermodynamic parameters of the
whole and the isolated catalytic domain of MMP-2 (cdMMP-2) has shown its inhibitory prop-
erties, indicating the presence of (at least) two binding sites for the peptide, both located
within the catalytic domain, only one of the two being topologically distinct from the catalytic
active groove. However, the different behavior between whole MMP-2 and cdMMP-2 envis-
ages the occurrence of an additional binding site for the peptide on the hemopexin-like
domain of MMP-2. Interestingly, mass spectrometry analysis has shown that α-DG (613–
651) peptide is cleavable even though it is a very poor substrate of MMP-2, a feature that
renders this molecule a promising template for developing a selective MMP-2 inhibitor.
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Introduction
Dystroglycan (DG) is a membrane receptor belonging to the dystrophin-glycoprotein complex
(DGC). DG is formed by two subunits, alpha-dystroglycan (α-DG) and beta-dystroglycan (β
-DG), that provide a link between the extracellular matrix and the cytoskeleton [1]. α-DG is a
highly glycosylated extracellular protein that interacts with laminin, agrin and other extracellu-
lar proteins [2, 3], whereas β -DG is a transmembrane protein, associated with actin through
dystrophin [4]. Inside the cell, β -DG is involved in a network of interactions with many pro-
teins, including some factors belonging to different signaling pathways [5, 6]. The two subunits
are held together by non-covalent interactions occurring between the C-terminal domain of
α-DG and the extracellular N-terminal domain of β -DG [7]. These interactions play a crucial
role for the integrity of the entire DGC [8], that is in turn responsible for the stability of the
plasma membrane, especially in the skeletal muscle and in the central nervous system, where
DG is mainly expressed [9]. Under pathological conditions, such as cancer and neuromuscular
diseases (including severe muscular dystrophies) [10], disruption of the DG subunits is often
associated to the over-expression of some members of the metalloproteinase (MMP) family
[11–15], which are Zn2+-dependent endopeptidases critical for tissue homeostasis and cell sig-
naling [16, 17]. The structural modular architecture of MMP family shows (from N-terminus
to C-terminus) a propeptide domain, which is removed upon enzyme activation, a catalytic
domain and a hemopexin-like domain, which are connected by a hinge region [18]. The iso-
lated catalytic domain of all MMP members retains the capability of cleaving linear peptidic
substrates according to the specific substrate selectivity of each single subclass of the family
[19]. Importantly, MMP gelatinases, namely MMP-2 and MMP-9, possess a unique additional
collagen binding domain (CBD), inserted within the MMP’s catalytic domain sequence [20].
The peculiarity of the CBD domain concerns its involvement in the recognition and binding
of protein substrates, a role exerted prevalently by the hemopexin-like domain in other MMPs,
providing an ancillary binding surface which governs the cleavage specificity of very complex
macromolecular substrates, such as 3D triple helical collagens [21–26].
Many physiological substrates for MMPs, including membrane proteins, are shed from the
cell surface, often showing distinct biological functions in the proteolyzed form [19, 27, 28]. In
particular, MMP gelatinases remove the extracellular N-terminal domain of β -DG, producing
a 30 kDa truncated form of β -DG [11, 29, 30]. Two molecular mechanisms, differing between
the two gelatinases, have been described in vitro for the shedding of the β -DG N-terminal
domain. Thus, MMP-9 operates the first cleavage, removing at the N-terminal region of about
60 amino acids, which is further degraded, and leaving an intact C-terminal fragment of about
30 amino acids [31]; on the other hand, MMP-2 completely disrupts the β -DG N-terminal
domain, producing multiple cleavages [32]. In vivo, disruption of the β -DG N-terminal
domain is likely to leave the C-terminal domain of α-DG exposed to a variety of endopepti-
dases, that exert their catalytic activity within the extracellular matrix. However, recent find-
ings report that double-targeting of MMP-2 and MMP-9 cannot prevent cleavage of β -DG in
sarcoglycanopathy [33]. Processing and secretion of N-terminal domain of α-DG in cell cul-
ture media has been previously reported [34]. Further, in vitro we have revealed that native α-
DG can be degraded by MMP-2, with the α-DG C-terminal domain representing the region
most susceptible to the protease activity [35]. Computational analysis on all MMP cleavage
sites reported in literature showed that MMPs cleave preferentially in exposed loops and in dis-
ordered regions of proteins [36]. No structural information is available for the α-DG C-termi-
nal domain, but a modeling study suggested the presence of an Ig-like domain for the region
approximately comprised between amino acids 500–600, followed by a coil-helix-coil motif
spanning the amino acids 601–651 [37]. In vitro, the recombinant α-DG C-terminal domain
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can be degraded by MMP-2, whereas a shorter co-purified α-DG-fragment is fully resistant to
the enzyme, suggesting the presence of a MMP-2 recognition site involving the missing amino
acids [35]. In this work, we have assigned by mass spectrometry the sequence of this shorter
fragment as α-DG (483–621), and we focused our investigation on the full C-term construct
α-DG (483–628), following its proteolysis kinetics by MMP-2. Overall, we confirmed the pro-
posed mechanism and showed that a peptide, spanning the last 39 amino acids of the α-DG C-
terminus, namely α-DG (613–651) peptide, can modulate (already within the nanomolar
range of concentrations) the MMP-2 catalysis of the entire enzyme and of its isolated catalytic
domain (cdMMP-2).
Materials and methods
Materials
The purity of Human recombinant MMP-2 of whole proenzymes (R&D System, London, UK)
and its catalytic domain cdMMP-2 (Biomol International) was measured by sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) according to the Laemmli’s method.
After the gels had been run, they were stained using a silver staining kit (Bio-Rad, Hercules,
CA, USA). The broad spectrum protein markers (Bio-Rad, Hercules, CA, USA) were used as
molecular weight standards. The stability of MMP-2 was checked by zymography (employing
as the substrate either gelatin or type I collagen) [38]. The MMP-2 is perfectly stable (without
undergoing any autocatalytic activity in the presence of the α-DG solution at 37˚C) for well
over 60 min, which covers by far the time period needed for the measurements of the catalytic
parameters (i.e.,15 minutes).
p-Hydroxybenzyl alchol resin (Wang) and N-α-Fmoc-L-amino acids used during chain
assembly were purchased from Iris Biotech GmbH (Marktredwitz, Germany). [2-(1H-benzo-
triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HBTU) was purchased from
Fluka (Buchs, Switzerland), N,N’-dimethylformamide (DMF) and trifluoroacetic acid (TFA)
were from Carlo Erba (Rodano, Italy). N,N’-diisopropylethylamine (DIEA), dichloromethane
(DCM), triisopropylsilane (TIPS), N-methyl pirrolidone (NMP) and all other organic reagents
and solvents, unless stated otherwise, were purchased in high purity from Sigma-Aldrich
(Steinheim, Germany). All solvents for solid-phase peptide synthesis (SPPS) were used without
further purification. HPLC grade acetonitrile and ultrapure 18.2 O water (MilliQ) were used
for the preparation of all solvents for liquid chromatography.
DNA manipulation
The full-length cDNA encoding for murine DG was used as a template to generate by PCR
two DNA construct corresponding to the C-terminal region of α-DG, α-DG(483–628).
Appropriate primers were used to amplify the DNA sequence of α-DG(483–628): forward
5’-CCCGTCGACAGTGGAGTGCCCCGTGGGGGAGAAC-3’ and reverse 5’-CCC
GAATTCTTATACCAAAGCAATTTTTCTTGTGAATG-3’,SalI and EcoRI restriction sites are
in bold type.
Protein expression and purification
The DNA construct obtained was purified and cloned into a bacterial vector which is appro-
priate to express the protein as thioredoxin fusion product, also containing an N-terminal
6His tag and a thrombin cleavage site. The recombinant fusion protein was expressed in
Escherichia coli BL21(DE3) Codon Plus RIL strain (Agilent Technologies, Australia), since no
glycosylation sites have been found in the native eukaryotic protein [39], and purified using
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nickel affinity chromatography. The construct of interest was obtained upon thrombin cleav-
age. Tricine/SDS-PAGE was used to check the purity of the recombinant proteins under
analysis.
Chemical synthesis and purification of the C-term peptide
Linear peptide was assembled on a Wang resin (0,6 mmol/g) in a 0.10 mmol scale. Resin was
properly swelled prior use with a NMP/DCM mixture. Peptide assembling was performed
automatically on a Biotage ALSTRA peptide synthesizer using a Fmoc-chemistry protocol.
Coupling of entering Fmoc-protected amino acids was performed using HBTU/DIEA (1:1:2, 4
equivalents excess over resin loading, 1 x 5min, 75 C). Deprotection steps were performed by
treatment with a 20% piperidine solution in DMF (2x5min, RT). Following each coupling or
deprotection step, resin-bound peptide was washed 5 times with DMF. Following chain assem-
bly, peptides were cleaved from the resin using a TFA 90%, Water 5%, Phenol 2.5%, TIPS 2.5%
mixture (2 hours, RT). Following precipitation in cold diethyl ether, crude peptides were col-
lected by centrifugation and subsequently washed with further cold diethyl ether to remove
scavengers. Peptides were then dissolved in a 50% aqueous acetonitrile 0.07% TFA buffer and
underwent RP-HPLC purification.
Analytical and semi-preparative Reversed Phase High Performance Liquid Chromatogra-
phy (RP-HPLC) were carried out on a Tri Rotar-VI HPLC system equipped with a MD-910
multichannel detector for analytical purposes or with a Uvidec-100-VI variable UV detector
for preparative purpose (all from JASCO, Tokyo, Japan). A Phenomenex Jupiter 5μ C18 90Å
column (150 x 4.6 mm) was used for analytical runs and a Phenomenex Jupiter 10μ C18 90Å
(250 x 21.2 mm) for peptide purification. Data were recorded and processed with Borwin soft-
ware. A linear gradient of eluent B (eluent A = H2O/ 3% CH3CN / 0.07% TFA, eluent B = 70%
CH3CN/ 30% H2O/ 0.07% TFA) was employed at a flow rate of 1mL/min for analytic pur-
poses. UV detection was recorded in the 220–320 nm range. Purification of the peptides was
achieved by preparative RP-HPLC at a flow rate of 14 mL/min using a linear gradient of eluent
B. Pure RP-HPLC fractions (>95%) were combined and lyophilized. Mass spectra were col-
lected separately.
Mass spectrometry analysis of the recombinant a-DG(483–628) domain
and of the α-DG(613–651) peptide
Recombinant α-DG (483–628) domain was separated on 1D-gel NuPAGE 4–12% (Novex,
Invitrogen) and stained with the Colloidal Blue Staining kit (Invitrogen). The stained bands
were cut, incubated with 10 mM DTT for 1h at 56˚C, then with 50 mM iodoacetamide for
45min at RT in the dark, subsequently dried before enzymatic digestion that was performed
with 12.5 ng/ml LysC or GluC (Roche) at 37˚C over night.
Samples containing the (613–651) peptide were cleaned by 30kDa cutoff filters to remove
MMP-2 and desalted by C18 Zip Tip (Millipore) before mass spectrometry analysis. Peptide
mixture deriving from the enzymatic reactions (α-DG (483–628) domain treated with LysC,
GluC or (613–651) peptide incubated with MMP2) were analyzed by nanoflow-reversed-phase
liquid chromatography tandem mass spectrometry (RP-LC-MS/MS) using an HPLC Ultimate
3000 (DIONEX, Sunnyvale, CA U.S.A) connected on line with a linear Ion Trap (LTQ,
Thermo, San Jose, CA). Peptides were desalted in a trap-column (AcclaimPepMap100 C18,
LC Packings, DIONEX) and then separated in a 10 cm long fused silica capillary (SilicaTipsFS
360-75-8, New Objective, Woburn, MA, USA), slurry-packed in-house with 5 μm, 200 Å pore
size C18 resin (Michrom BioResources, CA). Peptides were eluted using a 45 min long linear
gradient from 20% to 50% acetonitrile in presence of 0.1% formic acid at 300 nl/min flow rate,
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followed by 50 min during which the column was washed and then equilibrated again. Spectra
were acquired in positive ion mode (HV Potential 1.7–1.8kV) in a data-dependent mode: each
full MS spectrum was followed by the fragmentation of the five most abundant precursor ions.
MS/MS spectra were analyzed using the Proteome Discoverer 1.4 software (Thermo) and data-
base from Swiss-Prot containing E. coli proteins and / or α-DG sequence.
Enzymatic assays
Human MMP-2 proenzyme 2 was activated by incubating 0.1 mg/ml progelatinase solution
with 0.25 mM aminophenyl mercuric acid (Sigma, St. Louis, MO, USA) at 37˚C for 30 min-
utes. Whereas human recombinant cdMMP-2 human was dissolved in a solution of 50 mM
Tris/HCl (pH 7.2), 0.1M NaCl and 10 mMCaCl. The actual concentration of active MMP-2
(i.e. whole MMP2 and cdMMP2) was determined by the classic fluorimetric assay [38], follow-
ing the progressive decrease of hydrolysis (upon addition of an irreversible inhibitor, ilomastat
(GM 6001) which stoichiometrically inhibits MMPs) of the MCA- Pro-Leu-Gly-Leu-
DPA-Ala-Arg-NH2 fluorogenic substrate (λexc = 325 nm, λem = 398 nm). All measurements
were performed at 37˚C using a solution of 50 mM Tris–HCl, 0.1 M NaCl, 10 mM CaCl2 and
0.05% Brij 35 buffered at pH 7.3.
α-DG domain degradation assay
The α-DG domain degradation by MMP-2 was performed in 50 mM Tris–HCl, 0.1 M NaCl,
10 mM CaCl2 the mixtures were kept at 37˚C and small aliquots were harvested at different
time intervals (ranging from 0 and 18 hours). The reactions were stopped by the addition of
SDS-PAGE loading buffer containing 20 mM EDTA, boiled for 2 minutes and frozen to -80˚C
until they were used.
Equal aliquots from the incubation mixtures were collected at increasing times, the samples
were separated on gradient precast TRIS glycine 10–20% SDS-PAGE gels and these were
stained using 0.5% Commassie blue, followed by distaining until substrate bands were clearly
visible. The Coomassie blue electrophoretic spots corresponding to each time intervals were
analyzed by image analysis software (Image Quant TL, Amersham Biosciences). For the evalu-
ation of pixel intensity, the pixel brightness through the region of interest was measured and
plotted using Graphpad Prism v6 software. Histograms reported the relative amount intensity
(expressed as arbitrary units and converted to percentage according to the ratio = band inten-
sity at the starting point t = 0/ intensity at any given time interval). Data were presented as
means± standard deviation of three independent experiments. The difference between the two
groups was compared with one-way ANOVA followed by Tukey post-hoc test by GraphPad
Prism, version 6.0 GraphPad software (La Jolla Ca),  p< 0.05 was considered significant.
Modulation of the α-DG C-terminal peptide on the MMP-2 activity
Different concentrations of the α-DG peptide (i.e., final concentration range spanning
between 0 μM and 4 μM) were incubated with 0.07 μM active MMP-2 for 30 min at 37˚C to
allow the interaction to occur. In the case of the cdMMP2 the kinetics were performed employ-
ing 0.06 μM cdMMP-2 at different concentration of α-DG (613–651) peptide in the range
0–2 μM. Different concentrations of MCA fluorogenic peptide (i.e: from 5 to 15 mM) were
then added to this solution. The enzymatic reaction was recorded for 30 minutes at 37˚C. The
initial velocities were derived from the slopes within the first 15 minutes, which is the time
period during which the rate is constant and less than 10% of the substrate was degraded. This
ensured a steady-state condition for the first cleavage step, and it was a prerequisite for the sub-
sequent analysis steps.
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Results
Characterization of recombinant α-DG (483–628) domain by mass
spectrometry
As already shown in our previous work [35], the murine α-DG C-term domain (construct
expressed and purified in E. coli) displayed two electrophoretic bands: an upper band (~17
kDa) and a lower band (~ 15 kDa).
To verify the absence of contamination from E. coli and confirm the identity of the purified
α-DG (483–628) domain, the two bands have been enzymatically in gel-digested and analyzed
by LC-MS/MS. The analysis of both bands confirmed the presence of several peptides deriving
from the α-DG (483–628) domain and no contaminant proteins from E. coli were detected.
Moreover, whilst the peptide mixture from the upper band allowed to map the sequence until
the leucine at position 627, as revealed by the (608–627) peptide (Table 1 and Fig 1), the enzy-
matic digestion of the lower band produced the (608–621) peptide (Table 1 and Fig 1), which
is absent in the upper band. These data indeed suggest that the lower band is a degradation
product which co-purifies with the recombinant α-DG (483–628) domain, likely ending with
the isoleucine at position 621.
The α-DG (613–651) peptide inhibits MMP-2 processing of α-DG (483–
628) domain
Degradation kinetics of 7 μM α-DG (483–628) domain (see Fig 2) by 14 nM MMP-2 is ana-
lyzed by SDS-PAGE electrophoresis separation (Fig 2B, upper lanes). In line with our previous
work [35], the intensity of the ~ 17 kDa electrophoresis band progressively reduces its intensity
over time while, concurrently, the lower band (~ 15 kDa) is resistant to the MMP-2 proteolytic
Table 1. X Corr indicates cross-correlation score that is the sequest measure of the goodness of fit of experimental peptide fragments to theoretical spectra. Upper
band and Lower band refer to the bands visible in the gel in the Fig 2. z is the peptide charge detected.
Position Enzyme Peptide sequence Upper band Lower Band
X Corr z X Corr z
497–513 GluC LKNHIDRVDAWVGTYFE 4.91 2 4.74 2
499–515 LysC NHIDRVDAWVGTYFEVK 4.83 2 4.49 2
499–531 LysC NHIDRVDAWVGTYFEVKIPSDTFYDNEDTTTDK 5.11 5 5.31 5
513–540 GluC VKIPSDTFYDNEDTTTDKLKLTLKLRE 4.68 4 4.18 3
516–531 LysC IPSDTFYDNEDTTTDK 3.7 2 3.44 2
516–533 LysC IPSDTFYDNEDTTTDKLK 4.49 4 3.85 3
516–537 LysC IPSDTFYDNEDTTTDKLKLTLK 3.99 5 4.5 3
532–547 LysC LKLTLKLREQQLVGEK 4.01 4 3.04 3
541–572 GluC QQLVGEKSWVQFNSNSQLMYGLPDSSHVGKHE 3.38 2 3.13 4
547–572 GluC KSWVQFNSNSQLmYGLPDSSHVGKHE 6.81 3 7.17 3
547–572 GluC KSWVQFNSNSQLMYGLPDSSHVGKHE 6.49 3 6.84 3
548–570 LysC SWVQFNSNSQLmYGLPDSSHVGK 5.32 3 5.06 3
548–570 LysC SWVQFNSNSQLMYGLPDSSHVGK 4.93 5 4.85 3
548–580 LysC SWVQFNSNSQLMYGLPDSSHVGKHEYFMHATDK 3.2 2 3.05 5
573–590 GluC YFmHATDKGGLSAVDAFE 4.98 2 4.19 2
573–590 GluC YFMHATDKGGLSAVDAFE 4.37 4 3.92 2
581–595 LysC GGLSAVDAFEIHVHK 4.51 2 4.73 2
608–621 LysC ARLAGDPAPVVNDI 3.75 2
608–627 LysC ARLAGDPAPVVNDIHKKIAL 4.65 2
https://doi.org/10.1371/journal.pone.0192651.t001
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activity (Fig 2B, upper lanes). In order to unravel the role of the MMP-2 hemopexin-like
domain for the differential fragmentation, the proteolysis kinetics of the α-DG (483–628)
domain was also performed employing 30 nM of the isolated catalytic domain cdMMP-2. Fig
2C (upper lanes) shows that also the catalytic domain of MMP-2 (without the hemopexin-like
domain) retains the capability of degrading the α-DG (483–628) domain, even though in this
case the proteolytic cleavage of the α-DG domain appears less specific, the degradation occur-
ring both on the 17 kDa band and the 15 kDa band (Fig 2C, upper lanes). Therefore, the data
reported in Fig 2 clearly indicate that
1. the cleavage of the α-DG (483–628) domain by MMP-2 does not require the presence of
the hemopexin-like domain, since also cdMMP-2 enzymatically processes this domain;
2. the hemopexin-like domain likely plays a functional regulatory role by addressing MMP-2
toward a specific binding site, located within the C-terminal region between amino acid
positions 621–628, thus avoiding unspecific and widespread fragmentation of the all mac-
romolecular substrate.
3. The presence of the hemopexin-like domain in the whole MMP-2 protects the α-DG 483–
621 domain from the enzymatic processing.
Therefore, the hemopexin-like domain, though not required for the cleavage of the α-DG
(483–628) domain, is nonetheless crucial for proper substrate positioning of MMP-2, envisag-
ing its interaction with the 621–628 amino acid region.
In order to cast some light on the role of the 621–628 amino acid region on the α-DG pro-
cessing, we have chemically synthesized a human α-DG (613–651) peptide which shares a
closely similar amino acid sequence with murine α-DG 611–649 (see Fig 3). Therefore, we
have investigated the functional effect of the α-DG (613–651) peptide on the enzymatic pro-
cessing by MMP-2 of the α-DG (483–628) domain.
Fig 1. MS LC-MS/MS analysis of the purified αDG (483–628) domain. MS/MS spectra of the (608–621) peptide (A)
and (608–627) peptide (B) deriving from LysC digestion of lower and upper band of the gel shown in Fig 2,
respectively. Matched b and y ions are colored in red and blue, respectively.
https://doi.org/10.1371/journal.pone.0192651.g001
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Under the same experimental conditions, the degradation rate of the α-DG (483–628)
domain was much slower in the presence of 4 μM of α-DG peptide (Fig 2). Indeed, a signifi-
cant decrease of the 17 kDa band could be observed only after 5 hours of MMP-2 activity (Fig
2A, lower lanes) and a similar inhibitory effect was also detected in the case of cdMMP-2 (Fig
2B, lower lanes); furthermore, in the case of cdMMP-2, the presence of the α-DG (613–651)
peptide appears to inhibit even the enzymatic processing of the 15 kDa band (Fig 2B, lower
lanes). This feature suggests that the inhibitory effect is exerted through a direct binding of the
α-DG (613–651) peptide on cdMMP-2. This interaction not only interferes with the proteo-
lytic cleavage of the α-DG (613–651) sequence, but it also impairs the interaction of cdMMP-2
with additional substrate exosites, which can explain the extended and widespread fragmenta-
tion of the shorter α-DG (483–621) domain in the absence of the peptide (Fig 2B, upper lanes).
The similar inhibitory behavior suggests that the binding site of the α-DG (613–651) pep-
tide is located at the catalytic domain of MMP-2 and, given that the α-DG(483–628) domain
partially overlaps with the α-DG(613–651) peptide, this result indicates also that the interac-
tion of α-DG(483–628) domain with MMP-2 involves also the catalytic domain.
MMP-2 enzymatic activity toward a fluorogenic peptide is inhibited by the
human α-DG C-term (613–651) peptide
In order to determine the inhibitory mechanism, exerted by the α-DG (613–651) peptide on
MMP-2 and its cd-MMP-2, a small fluorogenic substrate (MCA-Pro-Leu-Gly-Leu-DPA-Ala-
Arg-NH2) was employed. Fig 4 reports the Lineweaver-Burk plots of the degradation kinetics
of the fluorogenic substrate carried out by the whole MMP-2 in the presence of increasing
amounts of the α-DG(613–651) peptide over a range of concentrations spanning between 0
and 4 μM (Fig 4A and 4B). It immediately comes out that the inhibitory effect displays a
Fig 2. The αDG (613–651) peptide affects the degradation of αDG (483–628) peptide (Panel A) Aminoacidic
sequences associated with each subunits of murine DG and its schematic representation. Enzymatic proteolysis profiles
of the purified α-DG C-terminal domain (483–628) construct by MMP-2 (Panel B), or by cdMMP-2 (Panel C) are
represented by the sodium dodecyl sulfate polyacrylamide gels stained with Coomassie blue. Four-point time course
was represented: time 0, time 30 s, time 1 hour, time 5 hours in the absence (upper panel) and in the presence (lower
panel) of 4 μM of the α-DG (613–651) peptide. Equal aliquots from the incubation mixtures were collected at
increasing times, the reaction was stopped and samples were separated by TRIS glycine 10–20% precast gel.
https://doi.org/10.1371/journal.pone.0192651.g002
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bimodal behavior, since at lower concentrations (i.e., between 23 nM and 0.4 μM) a non-com-
petitive mechanism seems operative (see Fig 4A), while at higher concentrations a competitive
inhibition comes into play (see Fig 4B). Such a bimodal behavior can be observed also in Fig
4C and 4D, which represents the Lineweaver-Burk plots of the degradation kinetics of the
fluorogenic substrate carried out by cdMMP-2 in the presence of increasing amounts of the α-
Fig 3. Comparison between the amino acid sequence of murine (upper panel) and human (lower panel) DG
(according to Swiss-Prot database). Amino acid sequences for signal peptides are in gray, for α-DG in bold, and for
α-DG in brown. Amino acid sequence of murine α-DG(483–628) are in bold green (upper panel) while the
corresponding sequence of human α-DG(485–630) is in bold blue. The amino acid sequence of the peptide derived
from the C-terminal portion of human α-DG (in the highlighted red rectangle), contains the sequence (613–630) that
overlaps with the corresponding mouse α-DG sequence (611–628), except for amino acids in light blue in the red
rectangle in lower panel.
https://doi.org/10.1371/journal.pone.0192651.g003
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DG(613–651) peptide, whose concentration values ranged between 0 and 2 μM (Fig 4C and
4D).
This behavior, which envisages the presence of (at least) two binding sites for the α-DG
(613–651) peptide on the catalytic domain of MMP-2, can be kinetically and thermodynami-
cally described by the scheme reported on Fig 5; where, 0kcat and 0Km are the observed catalytic
parameters in the absence of the peptide, Ka and Kb are the peptide dissociation constants to
the free enzyme for the two binding sites, α is the interaction parameter, which quantifies the
effect on Km of the α-DG(613–651) peptide binding to the first binding site (α> 1 indicates a
negative effect with a decreased affinity, α< 1 a positive effect and α = 1 no effect), β is the
interaction parameter which estimates the effect on kcat of the binding of α-DG(613–651) pep-
tide to the first binding site (β> 1 indicates a positive effect with an increased rate constant,
β< 1 a negative effect and β = 1 no effect).
Data reported in Figs 4 and 5 have been analyzed according to the following equation:
½E0
v
¼
obsKm
obskcat

1
½S
þ
1
obskcat
ðEq 1Þ
where [E0] is the total enzyme concentration, ν is the observed velocity (expressed as mol/s),
[S] is the substrate concentration, obskcat and obsKm are the observed catalytic parameters,
Fig 4. The effect of αDG (613–651) peptide on the catalytic parameters for the MMP-2 proteolysis. Lineweaver-
Burk plot of the enzymatic activity of 60 nM MMP-2 at 37˚C at pH 7.3 as a function of the fluorogenic substrate
concentration at different concentrations of α-DG(613–651) peptide, namely (panel A) 0 (o), 23 nM (x), 125 nM (),
200 nM (Δ) and 0.4,μM (25CA), and (panel B) 0.4 μM (o), 1 μM (x), 2 μM () and 4 μM (^). Continuous lines have
been obtained by applying Eqs. (1)–(3), employing parameters reported in Table 2. (Panel C): namely 0 (o), 23 nM (x),
60 nM () and 0.2 μM (^), and, (panel D) 0.2 μM (o), 0.6 μM (x) and 2 μM () and, (panel D) 0.2 μM (o), 0.6 μM (x)
and 2 μM (). Continuous lines have been obtained by applying Eqs. (1)–(3), employing parameters reported in
Table 2. Dashed line corresponds to the Lineweaver-Burk plot of the enzymatic activity of whole MMP-2 in the
absence. Dashed-dotted lines corresponds to the Lineweaver-Burk plot in the presence of the α-DG(613–651) peptide
0.2 μM and 2 μM α-DG(613–651) peptide in panel C and panel D, respectively. Where not shown, standard deviation
is smaller than symbol.
https://doi.org/10.1371/journal.pone.0192651.g004
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namely
obskcat ¼
0kcat 
ðKa  aþ b  ½PeptÞ
ðKa  aþ ½PeptÞ
ðEq 2Þ
and
obsKm ¼
0Km 
a  ðKa  Kb þ Kb  ½Pept þ ½Pept
2
Þ
Kb  ðKa  aþ ½PeptÞ
ðEq 3Þ
where 0kcat and 0Km are the catalytic paramenters in the absence of peptide and all other sym-
bols have the same meaning as described above.
The global fitting of data, reported in Fig 4, employing simultaneously Eqs (1), (2) and (3),
allowed to obtain all parameters reported in Table 2. The peptide concentration dependence of
catalytic parameters (kcat and Km) for both MMP-2 and cdMMP-2 confirms the appropriate-
ness of the scheme adopted (Figs 5 and 6, see Table 2). It is interesting to observe as the peptide
high affinity site for MMP-2 appears to be topologically distinct from the active site, envisaging
Fig 5. Thermodynamic and kinetic scheme for the effect of the αDG(613–651) peptide on the catalytic processing
of the fluorogenic peptide. Where, pept represents the αDG(613–651) peptide, 0kcat and 0Km are the observed catalytic
parameters in the absence of the peptide, Ka and Kb are the peptide dissociation constants to the free enzyme for the
two binding sites, α and β are the interaction parameters.
https://doi.org/10.1371/journal.pone.0192651.g005
Table 2. All parameters from scheme employed for the description of the modulatory effect by the α-DGC-term
peptide on the enzymatic activity of MMP-2 at pH 7.3 and 37˚C for the fluorogenic substrate (see Fig 5).
whole MMP-2 cd-MMP-2
0kcat (s-1) 29.6±4.5 26.1±4.1
0Km (M) 1.5(±0.3)×10−6 1.9(±0.5)×10−6
Ka (M) 3.5(±0.5)×10−8 3.5(±0.5)×10−8
Kb (M) 2.1(±0.4)×10−7 2.1(±0.4)×10−7
α 1.7±0.4 1.25±0.25
β 0.27±0.04 0.32±0.05
https://doi.org/10.1371/journal.pone.0192651.t002
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an allosteric modulation elicited by the α-DG (613–651) peptide on MMP-2, which reduces its
enzymatic activity through both a decrease of substrate affinity for the catalytic center (as from
α = 1.7±0.4, see Table 2 and Fig 6B) and a slowing down of the rate-limiting step along the
pathway of the substrate proteolytic cleavage (as from β = 0.27±0.04, see Table 2 and Fig 6A).
Further addition of peptide enables its interaction with MMP-2 active site cleft, thereby exert-
ing a competitive inhibition of the substrate enzymatic processing, as indicated by the lack of
an effect on kcat (see Figs 4B, 4D and 6A).
It can be observed that the catalytic parameters for the fluorogenic substrate are closely sim-
ilar (within the experimental errors) between the whole MMP-2 and cdMMP-2 (see Table 2
and Figs 4 and 6). The comparison between the inhibitory mechanism of the peptide operating
on the whole MMP-2 and on the cdMMP-2 reveals that for both species the α-DG (613–651)
peptide binding sites are located at the catalytic domain and apparently share the same dissoci-
ation constants (i.e., Ka and Kb, see Table 2). MMP-2 and cdMMP-2 slightly differ only for the
interaction parameters α and β (see Table 2), likely reflecting small structural differences refer-
rable to the presence or absence of the hemopexin-like domain.
A dampened activity of MMP-2 towards the α-DG (483–628) domain can
be achieved by saturating just one of the two binding sites
To functionally discriminate the effect of each binding site, on the basis of the estimated affin-
ity constants of the α-DG (613–651) peptide for the two sites (i.e: Ka = 3.5(±0.5)×10−8 M and
Kb = 2.1(±0.4)×10−7 M), the inhibition of the α-DG (483–628) domain processing has been
compared at two different concentrations of the peptide (i.e., 0.5 μM and 30 μM). These exper-
imental conditions ensure that the α-DG (613–651) peptide saturates only the allosteric site at
the lowest concentration, whereas both binding sites are occupied at the highest concentration.
Fig 7 displays the SDS-PAGE comparative analysis of the α-DG (483–628) domain digestion
by MMP-2 over the first 30 minutes, clearly showing that in the absence of inhibitor the 17
kDa band almost disappears (15±5% left over) (Fig 7, lane 1 and lane 2). The densitometry
analysis shows that the degree of inhibition exerted is very similar (Fig 7, lane 3 and lane 4),
despite the two concentrations of the α-DG (613–651) peptide differ by over 50 folds. Within
the first 15 minutes of proteolysis, the intensity of the 17 kDa band decreases by only 11±5%
under either low or high α-DG (613–651) peptide concentrations (Fig 7, lane 6 and lane 7,
respectively). Thus, the inhibition of MMP-2 occurs even when only the allosteric site, but not
the active site, is occupied by the α-DG (613–651) peptide. It clearly confirms that the observed
inhibitory effect by the α-DG (613–651) peptide is already exerted through the interaction
with the allosteric site even when the MMP-2 active site is available for substrate interaction.
Testing the proteolytic susceptibility of the α-DG (613–651) peptide to
MMP-2 by mass spectrometry analysis
Since human α-DG(613–651) peptide is a misfolded sequence of a physiological MMP-2 sub-
strate and one of the sites is able to bind the active site cleft (as indicated by the competitive
inhibition behavior, see Fig 4B), we have also evaluated whether MMP-2 can proteolytically
digest the α-DG (613–651) peptide. Therefore, we have maximized the chances of proteolysis,
not only by prolonging the incubation time (up to 18 hours), but also by increasing both
enzyme and peptide concentrations, respectively (i.e., 600 nM MMP-2 and 150 μM peptide).
LC-MS/MS analysis of α-DG (613–651) peptide, incubated with MMP-2, revealed the pres-
ence of new chromatographic peaks after a 5 hours incubation (18.9 min and 23.4 min reten-
tion times), not detected in the absence of the enzyme (Fig 8). Such peaks contain fragments
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deriving from the α-DG (613–651) peptide processed by MMP-2. In particular, we identified
the sequences (619–629) and (636–651) as the most relevant proteolytic products (Fig 8).
These data showed that α-DG(613–651) peptide can be cleaved by MMP-2, although
kinetic experiments indicated that it can allosterically inhibit the MMP-2 enzymatic activity
on both α-DG(483–628) domain and the fluorogenic peptide. Altogether, these data suggest
that the α-DG (613–651) peptide can be cleaved under extreme conditions, such as very high
concentrations of both substrate and enzyme (600 nM MMP-2 active enzyme and 150 μM α-
DG (613–651) peptide) and prolonged incubation time, while the α-DG(613–651) peptide
remains essentially stable under conditions employed for all kinetic experiments performed.
Discussion
In a previous paper we have shown that MMP-2 is able to enzymatically process the C-termi-
nal domain (corresponding to residues 483–628) of the murine α-DG, whereas a slightly
Fig 6. The αDG (613–651) peptide modulation of MMP-2 catalysis. Dependence on the α-DG(613–651) peptide
concentration of kcat (panel A), Km (panel B) and kcat/Km (panel C) for the enzymatic processing of the fluorogenic
peptide by whole MMP-2 (o) and by cdMMP-2 (x) at pH 7.3 and 37˚C, as obtained by the analysis of data reported in
Figs 4 and 5. Continuous lines have been obtained by applying Eqs (2) and (3), employing parameters reported in
Table 1. Arrows indicate the value of the parameter in the absence of the α-DG(613–651) peptide, which is represented
as “o” for the intact MMP-2 and as “x” for cdMMP-2.
https://doi.org/10.1371/journal.pone.0192651.g006
Fig 7. The αDG (613–651) peptide inhibition of the proteolysis of the αDG (483–628) domain by MMP-2. A)
SDS-PAGE gel Comassie blue stained showing the MMP-2 processing of 17 kDa band (α-DG C-terminal domain
(483–628)) in the presence of none (0), low (L) and high (H) concentration of the α-DGC-term peptide (615–651) (0.5
and 30 μM, respectively). A) Three-points time course: time 0 (lane 1), time 15’ (lane 2, 3 and 4), time 30’ (lane 5, 6 and
7). Control points (0): samples in the absence of α-DGC-term peptide (lane 1, 2 and 5). B) The amounts of intact α-DG
(483–628) domain were densitometry quantified; the histograms reported the relative means±SD band intensity of the
17 kDa band from three independent experiments. A one-way analysis of variance (ANOVA) was performed and
followed by Tukey’s honestly significant difference test. (n = 9 for each experimental conditions). () represent data
significantly different from the respective control (0) at p, 0.05.
https://doi.org/10.1371/journal.pone.0192651.g007
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shortened co-purified fragment (now characterized as α-DG(483–621), see Fig 1) could not be
degraded, suggesting that the 621–628 a.a. region is likely to include the sequence recognized
by the enzyme [35]. This mechanism finds support in the evidence, obtained in this work, that
a synthetic peptide, spanning the amino acids 613–651 of human α-DG (which has a sequence
highly homologous to murine DG) and partially overlapping with the C-terminus of murine
α-DG (Fig 3), is able to efficiently inhibit the enzymatic activity of MMP-2. Interestingly, the
α-DG (613–651) peptide also inhibits the α-DG (483–628) domain proteolysis catalyzed by
cdMMP-2, which can occur independently on the presence or not of the 621–628 a.a. region,
disrupting both the entire protein construct and its fragmentation product. Therefore, the
hemopexin-like domain indeed seems to play a role in substrate recognition, since, when it
does not assist the catalytic domain, induces a loss of the interaction specificity, making the
enzymatic fragmentation of α-DG(483–621) possible (see Fig 2B, upper panel).
The α-DG(613–651) peptide turned out to be an efficient allosteric inhibitor of MMP-2
even for the proteolysis on a small synthetic fluorogenic substrate, displaying a bimodal behav-
iour referrable to both a non-competitive inhibition (characterized by a higher affinity site
with Ka = 3.5(±0.5)×10-8M, see Table 2) and a competitive inhibition (characterized by a lower
affinity site with Kb = 2.1(±0.4)×10-7M, see Table 2). Therefore, based on our kinetic dissec-
tion, the peptide appears to have two binding sites on the catalytic domain of MMP-2, a first
Fig 8. LC-MS/MS analysis of the (613–651) peptide incubated with MMP-2. Chromatographic profiles of the (613–
651) peptide incubated for 5 hours without (A) or with (B) MMP-2. MS/MS spectra of the (636–651) peptide eluting at
RT 18.9 min (C) and (619–629) peptide eluting at RT 23.4 min (D). Matched b and y ions are colored in red and blue,
respectively, while precursor ions loosing H2O or NH3 are indicated in green.
https://doi.org/10.1371/journal.pone.0192651.g008
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one with a higher affinity and topologically distinct from the catalytic site, and a second one,
corresponding to the active site and displaying a lower affinity, where the synthetic peptide
competes with the substrate. A comparative analysis of the degradation kinetics of the small
fluorogenic peptide carried out by cdMMP-2 (where the hemopexin-like domain has been
recombinantly removed) in the presence of the α-DG(613–651) peptide revealed that the
MMP-2 and cdMMP-2 share both the high and low affinity binding sites for the inhibitory
peptide, with very similar dissociation constants, Ka and Kb (see Table 2). The allosteric modu-
lation of MMP proteolytic function exerted by exosites on the surface of the catalytic domain
has already been reported for others member of the MMP family [19]. Therefore, it is reason-
able to hypothesize that the binding sites are limited to the catalytic domain. However, our
data do not allow to rule out the possibility that the α-DG(613–651) peptide also interacts with
the hemopexin-like domain of whole MMP-2, interfering with its binding to the 621–628
amino acidic region.
Due to the close similarity between the amino acid sequence of human α-DG(613–651)
peptide and that of the murine C-terminal α-DG(483–628) domain, we can envisage a sce-
nario in which it is likely that the whole MMP-2 binds the α-DG(483–628) domain with very
high affinity through the hemopexin-like domain. Binding to this first anchoring site (likely
shaped by the 621–628 amino acide sequence) allows MMP-2 to direct its proteolytic cleavage
activity on a portion of the dystroglycan C-terminal domain comprised between amino acid
positions 483 and 621. On the other hand, the absence of this anchoring site (as in the case of
the 15 kDa fragment, see Fig 2A (upper lanes) or also in the presence of the α-DG (613–651)
peptide) impairs the enzymatic action of MMP-2 on the α-DG (483–628) domain (see Figs 2
and 7).
However, beside this anchoring site for the hemopexin-like domain of MMP-2 on the α-
DG 621–628 α-DG domain, an additional site (distinct from the active site) is present in
MMP-2, which interacts with the α-DG(483–621) domain. This additional non-competitive
site, which is characterized by a high affinity for the α-DG (613–651) peptide, is important for
Fig 9. Graphical sketch of the catalytic modulation of MMP-2 by αDG (613–651) peptide. The 613–651 sequence
of the human α-DG was used as template to chemically synthesize an MMP-2 inhibitor. This small peptide turned out
to modulate the catalysis of human MMP-2 mostly by the two binding sites at the catalytic domain.
https://doi.org/10.1371/journal.pone.0192651.g009
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the substrate recognition also in the absence of the hemopexin-like domain, as indicated by
the inhibitory effect elicited by the α-DG (613–651) peptide also on cd-MMP-2 (Fig 2B, lower
lanes). This additional site is likely located at the catalytic domain, possibly involving the CBD
domain of MMP-2, which predominantly contributes to substrate recognition by MMP-2 [40,
24].
As a whole, in MMP-2 two interactions sites (both distinct from the active site) seem to be
operative in the recognition of the α-DG (483–628) domain, one at the hemopexin-like
domain and one at the catalytic domain. The α-DG (613–651) peptide seems to be able to effi-
ciently impair their action already at a fairly low concentration; under these circumstances, an
allosteric inhibition occurs as the peptide does not prevent the proteolytic action of MMP-2 on
additional substrates (e.g. fluorogenic substrate proteolysis, see Figs 4B and 9). This feature,
which permits to modulate its inhibitory effect, together with the high kinetic stability of the
α-DG(613–651) peptide towards the catalytic activity of MMP-2, makes this dystroglycan-
derived synthetic peptide a “lead compound”, which may become a potential template for fur-
ther pharmaceutical development.
Acknowledgments
This work has been supported by funds from the Italian Space Agency (ASI SMEMCO n. DC-
DTE-2011-033 to U.T.).
Author Contributions
Conceptualization: Magda Gioia, Serena Camerini, Marco Crescenzi, Massimo Coletta.
Data curation: Magda Gioia, Diego Sbardella, MariaLuisa Casella, Serena Camerini, Alessan-
dro Gori.
Formal analysis: Magda Gioia, Serena Camerini, Massimo Coletta.
Funding acquisition: Umberto Tarantino, Paola Cozza.
Investigation: Magda Gioia, Giovanni Francesco Fasciglione, Manuela Bozzi.
Methodology: Giovanni Francesco Fasciglione, MariaLuisa Casella, Serena Camerini.
Project administration: Magda Gioia.
Supervision: Magda Gioia, Andrea Brancaccio.
Writing – original draft: Magda Gioia, MariaLuisa Casella, Serena Camerini, Massimo
Coletta.
Writing – review & editing: Magda Gioia, Giovanni Francesco Fasciglione, Diego Sbardella,
Francesca Sciandra, Marco Crescenzi, Andrea Brancaccio, Massimo Coletta, Manuela
Bozzi.
References
1. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, and Campbell KP. Pri-
mary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix.
Nature. 1992; 355: 696–702. https://doi.org/10.1038/355696a0 PMID: 1741056
2. Barresi R, and Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell
Sci. 2006; 119: 199–207. https://doi.org/10.1242/jcs.02814 PMID: 16410545
3. Sciandra F, Bozzi M, Bigotti MG, and Brancaccio A. The multiple affinities of α-dystroglycan. Curr Pro-
tein Pept Sci. 2013; 14: 626–634. PMID: 24206164
A substrate fragmentation-derived peptide regulates the enzymatic processing of alpha-DG from gelatinase A
PLOS ONE | https://doi.org/10.1371/journal.pone.0192651 February 15, 2018 17 / 19
4. Akhavan A, Griffith OL, Soroceanu L, Leonoudakis D, Luciani-Torres MG, Daemen A, et al. Loss of cell-
surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes. Can-
cer Res. 2012; 72: 2578–2588. https://doi.org/10.1158/0008-5472.CAN-11-3732 PMID: 22589276
5. Russo K, Di Stasio E, Macchia G, Rosa G, Brancaccio A, and Petricci TC. Charachterization of the β-
dystroglycan-growth factor receptor 2(Grb2) interaction. Biochem Biophys Res Commun. 2000; 274:
93–98. https://doi.org/10.1006/bbrc.2000.3103 PMID: 10903901
6. Spence HJ, Chen YJ, Batchelor CL, Higginson JR, Suila H, Carpen O, et al. Ezrin-dependent regulation
of the actin cytoskeleton by β dystroglycan Hum. Mol Genet. 2004; 13: 1657–1668.
7. Bozzi M, Sciandra F, and Brancaccio A. Role of gelatinases in pathological and physiological processes
involving the dystrophin-glycoprotein complex. Matrix Biol. 2015; 44–46: 130–137. https://doi.org/10.
1016/j.matbio.2015.02.005 PMID: 25701226
8. Heng S, Paule SG, Li Y, Rombauts LJ, Vollenhoven B, Salamonsen LA, et al. Post-translational
removal of α-dystroglycan N terminus by PC5/6 cleavage is important for uterine preparation for embryo
implantation in women. FASEB J. 2015; 29: 4011–4022. https://doi.org/10.1096/fj.14-269456 PMID:
26077903
9. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, et al. Post-translational disruption of
dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 2002; 418: 417–422.
https://doi.org/10.1038/nature00837 PMID: 12140558
10. Court FA, Zambroni D, Pavoni E, Colombelli C, Baragli C, Figlia G, et al. MMP2-9 cleavage of dystrogly-
can alters the size and molecular composition of Schwann cell domains. J Neurosci. 2011; 31: 12208–
12217. https://doi.org/10.1523/JNEUROSCI.0141-11.2011 PMID: 21865464
11. Losasso C, Di Tommaso F, Sgambato A, Ardito R, Cittadini A, Giardina B, et al. Anomalous dystrogly-
can in carcinoma cell lines. FEBS Lett. 2000; 484: 194–198. PMID: 11078877
12. Sgambato A, Camerini A, Amoroso D, Genovese G, De Luca F, Cecchi M, et al. Expression of dystro-
glycan correlates with tumor grade and predicts survival in renal cell carcinoma. Cancer biology & ther-
apy. 2007; 6: 1840–1846.
13. Kherif S, Lafuma C, Dehaupas M, Lachkar S, Fourier JG, Vrdiere-Sahuque M, et al. Expression of
matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injuried
and mdx muscles. Dev Biol. 1999; 205: 158–170. https://doi.org/10.1006/dbio.1998.9107 PMID:
9882504
14. Nadarajah VD, van Putten M, Chaouch A, Garrod P, Straub V, Lochmuller H, et al. Serum matrix metal-
loproteinase -9 (MMP-9) as biomaker for monitoring disease progression in Duchenne muscular dystro-
phy (DMD). Neuromuscul Disord. 2011; 21: 569–578. https://doi.org/10.1016/j.nmd.2011.05.011
PMID: 21724396
15. Bozzi M, Sciandra F, Ferri L, Torreri P, Pavoni E, Petrucci TC, et al. Concerted mutation of Phe residues
belonging to the β dystroglycan ectodomain strongly inhibits the interaction with α dystroglycan in vitro.
FEBS J. 2006; 273: 4929–4943. https://doi.org/10.1111/j.1742-4658.2006.05492.x PMID: 17018058
16. Sbardella D, Fasciglione GF, Gioia M, Ciaccio C, Tundo GR, Marini S, et al. Human matrix metallopro-
teinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol Aspects
Med. 2012; 33: 119–208. https://doi.org/10.1016/j.mam.2011.10.015 PMID: 22100792
17. Levin M, Udi Y, Solomonov I, and Sagi I. Next generation matrix metalloproteinase inhibitors—Novel
strategies bring new prospects. Biochim Biophys Acta. 2017; 1864: 1927–1939. https://doi.org/10.
1016/j.bbamcr.2017.06.009 PMID: 28636874
18. Sternlicht MD, and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev
Biol. 2001; 17: 463–516. https://doi.org/10.1146/annurev.cellbio.17.1.463 PMID: 11687497
19. Ratnikov BI, Cieplak P, Gramatikoff K, Pierce J, Eroshkin A, Igarashi Y, et al. Basis for substrate recog-
nition and distinction by matrix metalloproteinases. Proc Natl Acad Sci USA. 2014; 111; 4148–4155.
20. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, and Murphy G. Binding of gelatinases A
and B to type-I collagen and other matrix components. Biochem J. 1995; 309: 299–306. PMID:
7619071
21. Tam EM, Wu YI, Butler GS, Stack MS, and Overall CM. Collagen binding properties of the membrane
type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain. The ectodomain of the 44-kDa
autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage. J
Biol Chem. 2002; 277: 39005–39014. https://doi.org/10.1074/jbc.M206874200 PMID: 12145314
22. Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, et al. The hemopexin and
O-glycosylated domains tune gelatinaseB/MMP9 bioavailability via inhibition and binding to cargo
receptors. J Biol Chem. 2006; 281: 18626–18637. https://doi.org/10.1074/jbc.M512308200 PMID:
16672230
A substrate fragmentation-derived peptide regulates the enzymatic processing of alpha-DG from gelatinase A
PLOS ONE | https://doi.org/10.1371/journal.pone.0192651 February 15, 2018 18 / 19
23. Gioia M, Fasciglione GF, Marini S, D’Alessio S, De Sanctis G, Diekmann O, et al. Modulation of the cat-
alytic activity of neutrophil collagenase MMP-8 on bovine collagen I. Role of the activation cleavage and
of the hemopexin-like domain. J Biol Chem. 2002; 277: 23123–23130. https://doi.org/10.1074/jbc.
M110873200 PMID: 11953425
24. Gioia M, Monaco S, van den Steen PE, Sbardella D, Grasso G, Marini S, et al. The collagen binding
domain of gelatinase A modulates degradation of collagen IV by gelatinase B. J Mol Biol. 2009; 386:
419–434. https://doi.org/10.1016/j.jmb.2008.12.021 PMID: 19109975
25. Chung L, Dinakarpandian D, Yoshida N, Lauer-Fields JL, Fields GB, Visse R, et al. Collagenase
unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J. 2004; 23: 3020–3030. https://
doi.org/10.1038/sj.emboj.7600318 PMID: 15257288
26. Arnold LH, Butt LE, Prior SH, Read CM, Fields GB, and Pickford AR. The interface between catalytic
and hemopexin domains in matrix metalloproteinase-1 conceals a collagen binding exosite. J Biol
Chem. 2011; 286: 45073–45082. https://doi.org/10.1074/jbc.M111.285213 PMID: 22030392
27. Rizzo R, Trentini A, Bortolotti D, Manfrinato MC, Rotola A, Castellazzi M, et al. Matrix metalloprotei-
nase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol Cell Biochem.
2013; 381: 243–255. https://doi.org/10.1007/s11010-013-1708-5 PMID: 23737137
28. Overall CM, and Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev
Mol Cell Biol. 2007; 8: 245–257. https://doi.org/10.1038/nrm2120 PMID: 17299501
29. Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, et al. Processing of β-dystroglycan by
matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the
dystroglycan complex. Hum Mol Genet. 2001; 10: 1563–1569. PMID: 11468274
30. Paggi P, De Stefano ME, and Petrucci TC. Synaptic remodelling induced by axotomy of superior cervi-
cal ganglion neurons:involvement of metalloproteinase-2. J Physiol Paris. 2006; 99: 119–124. https://
doi.org/10.1016/j.jphysparis.2005.12.004 PMID: 16442271
31. Bozzi M, Inzitari R, Sbardella D, Monaco S, Pavoni E, Gioia M, et al. Enzymatic processing of β-dystro-
glycan recombinant ectodomain by MMP-9: identification of the main cleavage site. IUBMB Life. 2009;
61: 1143–1152. https://doi.org/10.1002/iub.273 PMID: 19946898
32. Sbardella D, Inzitari R, Iavarone F, Gioia M, Marini S, Sciandra F, et al. Enzymatic processing by MMP-
2 and MMP-9 of wild-type and mutated mouse β-dystroglycan. IUBMB Life. 2012; 64: 988–994. https://
doi.org/10.1002/iub.1095 PMID: 23129308
33. Fukai Y, Ohsawa Y, Ohtsubo H, Nishimatsu SI, Hagiwara H, Noda M, et al. Cleavage of β-dystroglycan
occurs in sarcoglycan-deficient skeletal muscle without MMP-2 and MMP-9. Biochem Biophys Res
Commun. 2017; 492: 199–205. https://doi.org/10.1016/j.bbrc.2017.08.048 PMID: 28821434
34. Saito F, Saito-Arai Y, Nakamura A, Shimizu T, and Matsumura K. Processing and secretion of the N-ter-
minal domain of α-dystroglycan in cell culture media. FEBS Lett. 2008; 582: 439–444. https://doi.org/
10.1016/j.febslet.2008.01.006 PMID: 18201566
35. Sbardella D, Sciandra F, Gioia M, Marini S, Gori A, Giardina B, et al. α-dystroglycan is a potential target
of matrix metalloproteinase MMP-2. Matrix Biol. 2015; 41: 2–7. https://doi.org/10.1016/j.matbio.2014.
11.007 PMID: 25483986
36. Kazanov MD, Igarashi Y, Eroshkin AM, Cieplak P, Ratnikov B, Zhang Y, et al. Structural determinants
of limited proteolysis. J Proteome Res. 2011; 10: 3642–3651. https://doi.org/10.1021/pr200271w
PMID: 21682278
37. De Rosa MC, Pirrolli M, Sciandra F, Giardina B, and Brancaccio A. A second Ig-like domain identified in
dystroglycan by molecular modelling and dynamics. J Mol Graph Model. 2011; 2: 1015–1024.
38. Gioia M, Fasciglione GF, Monaco S, Iundusi R, Sbardella D, Marini S, et al. pH dependence of the enzy-
matic processing of collagen I by MMP-1 (fibroblast collagenase), MMP-2 (gelatinase a) and MMP-14
ectodomain. J Biol Inorg Chem. 2010; 15: 1219–1232. https://doi.org/10.1007/s00775-010-0680-8
PMID: 20549272
39. Harrison R, Hitchen PG, Panico M, Morris HR, Mekhaiel D, Pleass RJ, et al. Glycoproteomic characteri-
zation of recombinant mouse α-dystroglycan. Glycobiology 2012; 22: 662–675. https://doi.org/10.1093/
glycob/cws002 PMID: 22241827
40. Gioia M, Monaco S, Fasciglione GF, Coletti A, Modesti A, Marini S, et al. Characterization of the mecha-
nisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14
recognize collagen I and enzymatically process the two α-chains. J Mol Biol. 2007; 368: 1101–1113.
https://doi.org/10.1016/j.jmb.2007.02.076 PMID: 17379243
A substrate fragmentation-derived peptide regulates the enzymatic processing of alpha-DG from gelatinase A
PLOS ONE | https://doi.org/10.1371/journal.pone.0192651 February 15, 2018 19 / 19
